Drug Profile


Alternative Names: Adelatinib; VRT-831509; VX-509

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Amides; Aminopyridines; Anti-inflammatories; Antirheumatics; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Jul 2014 Vertex completes a phase IIb trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russia, Serbia, Slovakia and Ukraine (NCT01590459) prior to July 2015
  • 01 Feb 2014 Vertex Pharmaceuticals completes a phase II trial in Rheumatoid arthritis in USA, South Africa, the Netherlands, Denmark, Lithuania & Estonia (NCT01754935)
  • 21 Oct 2013 Interim safety and efficacy data from a phase IIb trial in Rheumatoid arthritis released by Vertex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top